Skip to main content
logo
Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
7.54
-0.53 (-6.57%)
Mar 20, 2026, 4:00 PM EDT - Market closed

Company Description

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.

Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Minerva Neurosciences, Inc.
Minerva Neurosciences logo
CountryUnited States
Founded2007
IPO DateJul 1, 2014
IndustryBiotechnology
SectorHealthcare
Employees8
CEORemy Luthringer

Contact Details

Address:
1500 District Avenue
Burlington, Massachusetts 01803
United States
Phone617 600 7373
Websiteminervaneurosciences.com

Stock Details

Ticker SymbolNERV
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001598646
CUSIP Number603380205
ISIN NumberUS6033802058
Employer ID26-0784194
SIC Code2834

Key Executives

NamePosition
Dr. Remy Luthringer Ph.D.Executive Chairman and Chief Executive Officer
Geoffrey Robin Race F.C.M.A., M.B.A.President
Frederick W. Ahlholm CPASenior Vice President, Chief Financial Officer and Secretary
Joseph ReillySenior Vice President and Chief Operating Officer
William B. BoniVice President of Investor Relations and Corporate Communications
Prof. Michael Davidson M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Mar 19, 2026EFFECTNotice of Effectiveness
Mar 11, 2026S-3Registration statement under Securities Act of 1933
Mar 11, 202610-KAnnual Report
Mar 11, 20268-KCurrent Report
Mar 10, 2026144Filing
Mar 10, 2026144Filing
Mar 10, 2026144Filing
Feb 20, 2026SCHEDULE 13GFiling
Feb 17, 2026SCHEDULE 13GFiling
Feb 17, 2026SCHEDULE 13GFiling
View All SEC Filings